Literature DB >> 32398759

Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.

Yuanzhe Li1, Aya Ikeda1, Hiroyo Yoshino2, Genko Oyama1, Mitsuhiro Kitani3, Kensuke Daida1, Arisa Hayashida1, Kotaro Ogaki1, Kousuke Yoshida4, Takashi Kimura4, Yoshiaki Nakayama5, Hidefumi Ito5, Naoto Sugeno6, Masashi Aoki6, Hiroaki Miyajima7, Katsuo Kimura8, Naohisa Ueda8, Masao Watanabe9, Takao Urabe9, Masashi Takanashi1, Manabu Funayama1,2, Kenya Nishioka10, Nobutaka Hattori11,12.   

Abstract

Variants of leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD). We aimed to investigate the genetic and clinical features of patients with PD and LRRK2 variants in Japan by screening for LRRK2 variants in three exons (31, 41, and 48), which include the following pathogenic mutations: p.R1441C, p.R1441G, p.R1441H, p.G2019S, and p.I2020T. Herein, we obtained data containing LRRK2 variants derived from 1402 patients with PD (653 with sporadic PD and 749 with familial PD). As a result, we successfully detected pathogenic variants (four with p.R1441G, five with p.R1441H, seven with p.G2019S, and seven with p.I2020T) and other rare variants (two with p.V1447M, one with p.V1450I, one with p.T1491delT, and one with p.H2391Q). Two risk variants, p.P1446L and p.G2385R, were found in 10 and 146 patients, respectively. Most of the patients presented the symptoms resembling a common type of PD, such as middle-aged onset, tremor, akinesia, rigidity, and gait disturbance. Dysautonomia, cognitive decline, and psychosis were rarely observed. Each known pathogenic variant had a different founder in our cohort proven by haplotype analysis. The generation study revealed that the LRRK2 variants p.G2019S and p.I2020T were derived 3500 and 1300 years ago, respectively. Our findings present overviews of the prevalence and distribution of LRRK2 variants in Japanese cohorts.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32398759     DOI: 10.1038/s10038-020-0772-4

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  45 in total

1.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.

Authors:  Manabu Funayama; Kazuko Hasegawa; Etsuro Ohta; Noriko Kawashima; Masaru Komiyama; Hisayuki Kowa; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

Review 2.  What genetics tells us about the causes and mechanisms of Parkinson's disease.

Authors:  Olga Corti; Suzanne Lesage; Alexis Brice
Journal:  Physiol Rev       Date:  2011-10       Impact factor: 37.312

3.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Authors:  Owen A Ross; Alexandra I Soto-Ortolaza; Michael G Heckman; Jan O Aasly; Nadine Abahuni; Grazia Annesi; Justin A Bacon; Soraya Bardien; Maria Bozi; Alexis Brice; Laura Brighina; Christine Van Broeckhoven; Jonathan Carr; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Dennis W Dickson; Nancy N Diehl; Alexis Elbaz; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; J Mark Gibson; Rachel Gibson; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Suzanne Lesage; Chin-Hsien Lin; Timothy Lynch; Demetrius M Maraganore; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Sung Sup Park; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Jessie Theuns; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Simone van de Loo; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Matthew J Farrer
Journal:  Lancet Neurol       Date:  2011-08-30       Impact factor: 44.182

4.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.

Authors:  Alessio Di Fonzo; Christan F Rohé; Joaquim Ferreira; Hsin F Chien; Laura Vacca; Fabrizio Stocchi; Leonor Guedes; Edito Fabrizio; Mario Manfredi; Nicola Vanacore; Stefano Goldwurm; Guido Breedveld; Cristina Sampaio; Giuseppe Meco; Egberto Barbosa; Ben A Oostra; Vincenzo Bonifati
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

5.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

Authors:  Manabu Funayama; Kazuko Hasegawa; Hisayuki Kowa; Masaaki Saito; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

Review 6.  Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review.

Authors:  L Correia Guedes; J J Ferreira; M M Rosa; M Coelho; V Bonifati; C Sampaio
Journal:  Parkinsonism Relat Disord       Date:  2009-11-30       Impact factor: 4.891

7.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

8.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

9.  Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).

Authors:  Radek Linhart; Sarah Anne Wong; Jieyun Cao; Melody Tran; Anne Huynh; Casey Ardrey; Jong Min Park; Christine Hsu; Saher Taha; Rentia Peterson; Shannon Shea; Jason Kurian; Katerina Venderova
Journal:  Mol Neurodegener       Date:  2014-06-11       Impact factor: 14.195

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  7 in total

Review 1.  Molecular genetics of Parkinson's disease: Contributions and global trends.

Authors:  Manabu Funayama; Kenya Nishioka; Yuanzhe Li; Nobutaka Hattori
Journal:  J Hum Genet       Date:  2022-07-11       Impact factor: 3.755

2.  A Novel LRRK2 Variant p.G2294R in the WD40 Domain Identified in Familial Parkinson's Disease Affects LRRK2 Protein Levels.

Authors:  Jun Ogata; Kentaro Hirao; Kenya Nishioka; Arisa Hayashida; Yuanzhe Li; Hiroyo Yoshino; Soichiro Shimizu; Nobutaka Hattori; Yuzuru Imai
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

Review 3.  Modelling the functional genomics of Parkinson's disease in Caenorhabditis elegans: LRRK2 and beyond.

Authors:  Rachael J Chandler; Susanna Cogo; Patrick A Lewis; Eva Kevei
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

Review 4.  Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies.

Authors:  Kenya Nishioka; Yuzuru Imai; Hiroyo Yoshino; Yuanzhe Li; Manabu Funayama; Nobutaka Hattori
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

5.  Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson's disease.

Authors:  Toshiki Tezuka; Daisuke Taniguchi; Mariko Sano; Tomoyo Shimada; Yutaka Oji; Taiji Tsunemi; Aya Ikeda; Yuanzhe Li; Hiroyo Yoshino; Jun Ogata; Kahori Shiba-Fukushima; Manabu Funayama; Kenya Nishioka; Yuzuru Imai; Nobutaka Hattori
Journal:  NPJ Parkinsons Dis       Date:  2022-08-05

Review 6.  Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.

Authors:  Gunjan Thakur; Vikas Kumar; Keun Woo Lee; Chungkil Won
Journal:  Genes (Basel)       Date:  2022-08-11       Impact factor: 4.141

Review 7.  Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.

Authors:  Paweł Turski; Iwona Chaberska; Piotr Szukało; Paulina Pyska; Łukasz Milanowski; Stanisław Szlufik; Monika Figura; Dorota Hoffman-Zacharska; Joanna Siuda; Dariusz Koziorowski
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.